Development of FGI-106 as a broad-spectrum therapeutic with activity against members of the family Bunyaviridae

References

• Fields BN, Knipe DM, Griffin DE. Fields’ Virology. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams and Wilkins; 2007.
   Google Scholar
• Meegan JM, Bailey CL. Rift Valley Fever. In: Monath TP, editor. The Arboviruses: Epidemiology and Ecology. Boca Raton, FL: CRC Press; 1989; IV:51–76.
   Google Scholar
• Flick R, Bouloy M. Rift Valley fever virus. Curr Mol Med. 2005;5(8):827–834.
   Web of Science ®Google Scholar
• Canonico PG, Kende M, Luscri BJ, Huggins JW. In-vivo activity of antivirals against exotic RNA viral infections. J Antimicrob Chemother. 1984;14(Suppl A):27–41.
   PubMedGoogle Scholar
• Huggins JW, Robins RK, Canonico PG. Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses. Antimicrob Agents Chemother. 1984;26(4):476–480.
   PubMed Web of Science ®Google Scholar
• Huggins JW, Kim GR, Brand OM, McKee KT Jr. Ribavirin therapy for Hantaan virus infection in suckling mice. J Infect Dis. 1986;153(3):489–497.
   Web of Science ®Google Scholar
• Peters CJ, Reynolds JA, Slone TW, Jones DE, Stephen EL. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res. 1986;6(5):285–297.
   PubMed Web of Science ®Google Scholar
• Cassidy LF, Patterson JL. Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob Agents Chemother. 1989;33(11):2009–2011.
   PubMed Web of Science ®Google Scholar
• Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis. 1989;11(Suppl 4):S750-S761.
   PubMedGoogle Scholar
• Watts DM, Ussery MA, Nash D, Peters CJ. Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am J Trop MedHyg. 1989;41(5):581–585.
   Web of Science ®Google Scholar
• Tignor GH, Hanham CA. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. Antiviral Res. 1993;22(4):309–325.
   Web of Science ®Google Scholar
• Chung DH, Sun Y, Parker WB, et al. Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus. J Virol. 2007;81(21):11722–11729.
   Web of Science ®Google Scholar
• Gowen BB, Wong MH, Jung KH, et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother. 2007;51(9):3168–3176.
   PubMed Web of Science ®Google Scholar
• Chung DH, Kumarapperuma SC, Sun Y, et al. Synthesis of 1-beta- D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus. Antiviral Res. 2008;79(1):19–27.
   Web of Science ®Google Scholar
• Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res. 2008;78(1):162–169.
   Web of Science ®Google Scholar
• Rusnak JM, Byrne WR, Chung KN, et al. Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antiviral Res. 2009;81(1):68–76.
   PubMed Web of Science ®Google Scholar
• Snell NJ. Ribavirin - current status of a broad spectrum antiviral agent. Expert Opin Pharmacother. 2001;2(8):1317–1324.
   PubMedGoogle Scholar
• Borio L, Inglesby T, Peters CJ, et al; Working Group on Civilian Biodefense. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 2002;287(18):2391–2405.
   PubMed Web of Science ®Google Scholar
• Aman MJ, Kinch MS, Warfield K, et al. Development of a broad- spectrum antiviral with activity against Ebola virus. Antiviral Res. 2009;83(3):245–251.
   PubMed Web of Science ®Google Scholar
• Hooper JW, Larsen T, Custer DM, Schmaljohn CS. A lethal disease model for hantavirus pulmonary syndrome. Virology. 2001 ;289(1):6–14.
   Web of Science ®Google Scholar
• Causey OR, Kemp GE, Madbouly MH, David-West TS. Congo virus from domestic livestock, African hedgehog, and arthropods in Nigeria. Am J Trop Med Hyg. 1970;19(5):846–850.
   Web of Science ®Google Scholar
• Shepherd AJ, Swanepoel R, Leman PA, Shepherd SP. Comparison of methods for isolation and titration of Crimean-Congo hemorrhagic fever virus. J Clin Microbiol. 1986;24(4):654–656.
   Web of Science ®Google Scholar
• Peters CJ, Linthicum KJ. Rift Valley Fever. In: Beran GW, Steele JH, editors. Handbook of Zoonoses, Section B. Viral. Boca Raton, FL: CRC Press; 1994:125–138.
   Google Scholar
• Soldan SS, Gonzalez-Scarano F. Emerging infectious diseases: the Bunyaviridae. JNeurovirol. 2005;11(5):412–423.
   PubMed Web of Science ®Google Scholar
• Balkhy HH, Memish ZA. Rift Valley fever: an uninvited zoonosis in the Arabian peninsula. Int J Antimicrob Agents. 2003;21(2):153–157.
   PubMed Web of Science ®Google Scholar
• Madani TA, Al-Mazrou YY, Al-Jeffri MH, et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis. 2003;37(8):1084–1092.
   PubMed Web of Science ®Google Scholar
• Fisher-Hoch SP, Khan JA, Rehman S, et al. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet. 1995;346(8973):472–475.
   PubMed Web of Science ®Google Scholar